文献速递肝病消化道肿瘤与早癌

微小RNA-223通过靶向肝细胞中多种炎症和致癌基因改善非酒精性脂肪性肝炎及癌症

MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
PubMed 文献 · Hepatology · 2019-06-05

该研究在高脂饮食小鼠和人类非酒精性脂肪性肝炎样本中发现肝细胞微小RNA-223(miR-223)升高;miR-223基因缺失可诱导小鼠出现脂肪变性、炎症、纤维化及肝细胞癌;体外实验显示Cxcl10和Taz是miR-223下游靶点,miR-223可能成为非酒精性脂肪性肝炎治疗靶点。

要点

  • 高脂饮食小鼠及人类非酒精性脂肪性肝炎样本中肝细胞miR-223表达升高。
  • miR-223基因敲除小鼠长期高脂饮食后出现脂肪变性、炎症、纤维化及肝细胞癌。
  • Cxcl10和Taz是miR-223下游靶点,miR-223可能成为非酒精性脂肪性肝炎治疗靶点。

核心结论

  • 高脂饮食喂养的miR-223基因敲除小鼠可发展为全谱系非酒精性脂肪性肝病,是临床相关的小鼠模型。
  • miR-223通过抑制肝脏Cxcl10和Taz表达在控制单纯脂肪变性向非酒精性脂肪性肝炎进展中起关键作用,并可能成为治疗非酒精性脂肪性肝炎的靶点。

研究设计与样本

  • 研究检测了高脂饮食喂养小鼠和人类非酒精性脂肪性肝炎样本中肝细胞miR-223的表达。
  • 通过miR-223基因敲除小鼠长期高脂饮食观察非酒精性脂肪性肝病表型,并进行微阵列分析和体外实验。

主要发现

  • 在人类中,仅20%-40%的脂肪肝患者进展为非酒精性脂肪性肝炎,而高脂饮食喂养小鼠发生脂肪肝但不易进展为非酒精性脂肪性肝炎。
  • 高脂饮食喂养小鼠肝细胞和人类非酒精性脂肪性肝炎样本中miR-223表达高度升高。
  • 长期高脂饮食喂养的miR-223基因敲除小鼠出现脂肪变性、炎症、纤维化及肝细胞癌。
  • 微阵列分析显示,与野生型小鼠相比,高脂饮食喂养的miR-223基因敲除小鼠肝脏中多种炎症基因和癌症相关基因表达更高,包括Cxcl10和Taz。
  • 体外实验表明Cxcl10和Taz是miR-223的两个下游靶点,过表达miR-223可降低培养肝细胞中它们的表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to more severe forms of liver injury including nonalcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). In humans, only 20%-40% of patients with fatty liver progress to NASH, and mice fed a high-fat diet (HFD) develop fatty liver but are resistant to NASH development. To understand how simple steatosis progresses to NASH, we examined hepatic expression of anti-inflammatory microRNA-223 (miR-223) and found that this miRNA was highly elevated in hepatocytes in HFD-fed mice and in human NASH samples. Genetic deletion of miR-223 induced a full spectrum of NAFLD in long-term HFD-fed mice including steatosis, inflammation, fibrosis, and HCC. Furthermore, microarray analyses revealed that, compared to wild-type mice, HFD-fed miR-223 knockout (miR-223KO) mice had greater hepatic expression of many inflammatory genes and cancer-related genes, including (C-X-C motif) chemokine 10 (Cxcl10) and transcriptional coactivator with PDZ-binding motif (Taz), two well-known factors that promote NASH development. In vitro experiments demonstrated that Cxcl10 and Taz are two downstream targets of miR-223 and that overexpression of miR-223 reduced their expression in cultured hepatocytes. Hepatic levels of miR-223, CXCL10, and TAZ mRNA were elevated in human NASH samples, which positively correlated with hepatic levels of several miR-223 targeted genes as well as several proinflammatory, cancer-related, and fibrogenic genes. Conclusion: HFD-fed miR-223KO mice develop a full spectrum of NAFLD, representing a clinically relevant mouse NAFLD model; miR-223 plays a key role in controlling steatosis-to-NASH progression by inhibiting hepatic Cxcl10 and Taz expression and may be a therapeutic target for the treatment of NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. He Y, Hwang S, Cai Y, et al. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes. Hepatology. 2019. PMID: 30964207. doi:10.1002/hep.30645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。